Amgen Inc. (AMGN)
Symbol Info
Listed Symbol AMGN
Name Amgen Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $5.28
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $22,533,000,000
Latest Fiscal EPS $12.60
Price Info
21 Day Moving Average $195.6252
21 Day EMA $196.594680
50 Day Moving Average $197.9313
50 Day EMA $194.839830
200 Day EMA $187.556600
200 Day Moving Average 185.698060
52 Week High $211.90
52 Week Low $166.30
52 Week Change $6.771200
Alpha 0.000289
Beta 1.0754
Standard Deviation 0.066051
R2 0.312937
Periods 60
Share Information
10 Day Average Volume 2,072,894
20 Day Average Volume 2,232,752
30 Day Average Volume 2,481,669
50 Day Average Volume 3,056,603
Outstanding Shares 599,701,222
Float Shares 596,779,620
Percent Float 99.51%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 3,069
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 17,718,780
Institute Holdings Percent -
Institute Sold Previous 3 Months 46,158,456
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 5
Insider Holdings Percent 0.50%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,921,602
Price Change
7 Day Price Change $5.2100067
7 Day Percent Change 2.66%
21 Day Price Change $3.8600006
21 Day Percent Change 1.96%
30 Day Price Change $4.9600067
30 Day Percent Change 2.53%
Month To Date Price Change $7.2900
Month To Date Percent 3.77%
90 Day Price Change $24.052230
90 Day Percent Change 13.61%
Quarter To Date $7.290009
Quarter To Date Percent 3.77%
180 Day Price Change $11.669815
180 Day Percent Change 6.17%
200 Day Price Change $17.104187
200 Day Percent Change 9.31%
Year To Date $10.620056
Year To Date Percent 5.58%
Profile
Description Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
Details
Issue Type CS
Market Cap $120,420,005,378
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 599,701,222
CEO Robert A. Bradway
Employees 21,500
Last Audit UQ
Classification
CIK 0000318154
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Website http://www.amgen.com
Facisimile +1 805 447-1010
Telephone +1 805 447-1000
Email investor.relations@amgen.com
Key Ratios
Profitability
EBIT Margin 44.70
EBITDA Margin 53.2
Pre-Tax Profit Margin 37.3
Profit Margin Cont 36.17
Gross Margin 82.20
Profit Margin TOT 36.17
Income Statements
Revenue $16,861,000,000
Revenue Per Share $28.1157
Revenue 3 Years $-3.55
Revenue 5 Years $0.91
Valuation Measures
PE Ratio 15.00
Enterprise Value $124,904,183,469
Price To Sales 7.141926
Price To Free Cash 33.900000
PE High Last 5 Years 78.1
Price To Book 10.5
Price To Cash Flow 12.3
PE Low Last 5 Years 14.3
Price To Tangible Book -10.6
Financial Strength
Total Debt To Equity 2.8
Int Coverage 7.6
Current Ratio 2.9
Leverage Ratio 6.2
Quick Ratio 2.4
Long Term Debt To Capital 0.72
Assets
Receivables Turnover 1.9
Invoice Turnover 1.40
Assets Turnover 0.10
Management Effectiveness
Return Assets 12.53
Return On Equity 61.92
Return On Capital 18.86
Dividends
Dividend 3 Years $12.64
Dividend 5 Years $19.17
Ex Dividend Date 2019-08-14 00:00:00.0
Dividend Rate $5.80
Dividend Yield 2.89%
Payment Type Cash


Your Recent History
NASDAQ
AMGN
Amgen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.